Debiopharm Group™ has announced that they have signed a one-year collaboration agreement with Quartz Bio, the Clinical Bioinformatics Research Organization leader in precision biomarker discovery.
Under the research framework, Quartz Bio will apply its leading expertise in bioinformatics to support Debiopharm translational projects in terms of computational analyses and biomarker discovery.
Projects are expected to range from preclinical Next-Generation Sequencing to clinical biomarker data analyses.
“We are delighted to collaborate with Debiopharm,” said Dr. Jerome Wojcik, CEO of Quartz Bio. “Debiopharm’s pioneering biomarker projects are a unique opportunity for Quartz Bio to contribute to the implementation of Precision Medicine, thus demonstrating that bioinformatics science can bring substantial benefits to patients”.
“We look forward to collaborating with Quartz Bio,” commented Dr. Hiroaki Tanaka, Director of Personalized Medicine at Debiopharm.
Dr. Tanaka continued, “Their longstanding clinical bioinformatics experience made them an ideal partner to support our biomarker projects in our clinical trials and extract from data the relevant information required for personalized therapy development”.